Ardelyx Q3 2025 Earnings Report

Ardelyx EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.07
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Ardelyx Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $100.44 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Ardelyx Announcement Details

• Quarter: Q3 2025
• Date: 10/30/2025
• Time: After Market Closes
• Conference Call Date: Thursday, October 30, 2025
• Conference Call Time: 4:30PM ET

Ardelyx (NASDAQ:ARDX) (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders. The company is advancing RDX8940, a non‐systemic, gut‐restricted TGR5 agonist intended for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases. Additional programs focus on novel mechanisms to manage uremic toxins and intestinal sodium balance, reinforcing Ardelyx’s emphasis on gut‐targeted therapies that may improve patient outcomes without the safety risks of systemic drug exposure.

Founded in 2010 and headquartered in San Mateo, California, Ardelyx operates research and development facilities in the Bay Area, with a commercial infrastructure supporting product launch and patient access in the United States. The company has forged strategic collaborations—most notably with Mitsubishi Tanabe Pharma in Japan for the development and commercialization of tenapanor. Ardelyx’s leadership team, led by President and Chief Executive Officer Michael A. Raab, combines experience in drug discovery, regulatory affairs and commercial operations to drive its mission of bringing new treatment options to patients with high unmet medical needs.